<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2022000300007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Ranibizumab intravítreo para el tratamiento de oclusiones vasculares retinianas: análisis mediante tomografía de coherencia óptica]]></article-title>
<article-title xml:lang="en"><![CDATA[Intravitreal Ranibizumab for the Treatment of Retinal Vascular Occlusions: Analysis Using Optical Coherence Tomography]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arcentales Chaw]]></surname>
<given-names><![CDATA[Paul Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arteaga Loor]]></surname>
<given-names><![CDATA[Genny del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vinces Chancay]]></surname>
<given-names><![CDATA[Jairo Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villafuerte Mera]]></surname>
<given-names><![CDATA[Marcos Rolando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[De la Peña Consuegra]]></surname>
<given-names><![CDATA[Geilert]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Técnica de Manabí Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Manabí ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2022000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2022000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El uso del medicamento ranibizumab intravítreo favorece la reducción del edema macular generador de las oclusiones vasculares retinianas causantes de la pérdida visual.  Objetivo: Evaluar la eficacia y seguridad de la administración intravítreo de ranibizumab en el cambio de espesor macular central en las oclusiones vasculares retinianas analizado mediante tomografía de coherencia óptica.  Material y métodos:  Se desarrolló un estudio de tipo retrospectivo, analítico, correlacional y observacional de campo con diseño no experimental en 125 pacientes mayores de 30 años con oclusión vascular retiniana diagnosticados en la consulta de oftalmología del Hospital &#8220;Teodoro Maldonado Carbó&#8221; durante enero de 2017 a junio de 2018. La técnica ANOVA compara las medias para determinar mediante el proceso de contraste de hipótesis si existen diferencias estadísticamente significativas entre estas.  Resultados: El análisis de la agudeza visual con escala logMAR demostró diferencias estadísticamente significativas entre los promedios obtenidos 3 meses antes y después de la aplicación del tratamiento (p=0,0001). Se encontró 28,8 % de efectos adversos. Con frecuencia en aumento de presión intraocular (4 %), sequedad ocular (16 %) y hemorragia conjuntival (11,2 %).  Conclusiones:  El ranibizumab en oclusiones vasculares retinianas proporciona una mejor agudeza visual corregida en relación con el grosor macular, favorece el desarrollo de nuevos vasos sanguíneos a partir de vasos preexistentes desde migración de células endoteliales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  The use of the intravitreal ranibizumab favors the reduction of the macular edema that generates retinal vascular occlusions that cause visual loss.  Objective:  To evaluate the efficacy and safety of the intravitreal administration of ranibizumab in the change in central macular thickness in retinal vascular occlusions analyzed by optical coherence tomography.  Material and methods:  A retrospective, analytical, correlational and observational field study with a non-experimental design was carried out on 125 patients over 30 years of age diagnosed with retinal vascular occlusion in the Ophthalmology Service of &#8220;Teodoro Maldonado Carbó&#8221; Hospital during the period between January 2017 and June 2018. The ANOVA technique was used to compare means in order to determine, through the hypothesis contrast process, if there are statistically significant differences between them.  Results:  Visual acuity analysis using the logMAR scale showed statistically significant differences between the averages obtained 3 months before and after the application of the treatment (p = 0.0001). In addition, 28,8 % of adverse effects were found. The most frequent ones included increased intraocular pressure (4 %), dry eyes (16 %), and conjunctival hemorrhage (11,2 %).  Conclusions:  In retinal vascular occlusions, Ranibizumab provides a better corrected visual acuity in relation to macular thickness, favors the development of new blood vessels from pre-existing vessels from endothelial cell migration.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[oclusión de la vena retiniana]]></kwd>
<kwd lng="es"><![CDATA[oclusión de la arteria retiniana, factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[retina, Tomografía de Coherencia Óptica]]></kwd>
<kwd lng="en"><![CDATA[Retinal vein occlusion]]></kwd>
<kwd lng="en"><![CDATA[retinal artery occlusion, risk factors]]></kwd>
<kwd lng="en"><![CDATA[retina, Optical Coherence Tomography]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim Jae]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chang Young]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kim Jong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kim Chul]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lee Dong]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion]]></article-title>
<source><![CDATA[Ophthalmologica [Internet]]]></source>
<year>2017</year>
<volume>227</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>132-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koyagui]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the effectiveness of intravitreal ranibizumab for the treatment of diabetic macular edema in vitrectomized and non-vitrectomized eyes]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2017</year>
<volume>238</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>21-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rey]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Algunas consideraciones sobre el edema macular diabético]]></article-title>
<source><![CDATA[MEDISAN]]></source>
<year>2017</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>628-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Sociedad Oftalmologica de la Comunidad Valenciana</collab>
<source><![CDATA[Anatomía del ojo]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Valencia ]]></publisher-loc>
<publisher-name><![CDATA[SOCV]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schutze]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Imágenes para BRVO y CRVO]]></source>
<year>2011</year>
<publisher-loc><![CDATA[EE UU ]]></publisher-loc>
<publisher-name><![CDATA[Retina Today]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turello]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pasca]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Daminato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retinal vein occlusion: evaluation of "classic" and "emerging" risk ant treatment]]></article-title>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2010</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>459-64</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pineda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carriosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical aspects relevant to the diagnosis of retinal venous occlusions: A review]]></article-title>
<source><![CDATA[Cien Tecnol Salud Vis Ocul]]></source>
<year>2016</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91-111</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keren]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Loewenstein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coscas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis, prevention, diagnosis and management of of retinal vein occlusion]]></article-title>
<source><![CDATA[World J Ophthalmol]]></source>
<year>2014</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>92-112</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arellano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Paralva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moncayo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Maldonado]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fármacos antiangiogenicos en enfermedades neovasculares de la retina]]></article-title>
<source><![CDATA[Rev Científica Ciencias Médicas]]></source>
<year>2017</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>Instituto Nacional Estadisticas de Ecuador</collab>
<source><![CDATA[Anuario de Estadísticas Hospitalarias Camas y Egresos]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[INEE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Lovie]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New design principles for visual acuity charts]]></article-title>
<source><![CDATA[Am J Optom Physiol Opt]]></source>
<year>1976</year>
<volume>53</volume>
<page-range>740-5</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Muraoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Oot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Murakami]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morphological and functional changes of the retinal vessels in the retinal vein occlusion of the branch: angiography study by optical coherence tomography]]></article-title>
<source><![CDATA[Am J Ophthalmol]]></source>
<year>2017</year>
<volume>182</volume>
<page-range>168-79</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Encuesta de ceguera y deficiencia visual evitable en Panamá]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2014</year>
<volume>36</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahid]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Hossain]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Amoaku]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratamiento de la oclusión de la vena retiniana. La terapia individualizada es crucial para buenos resultados para el paciente]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[IntraMed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pineda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carriosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical aspects relevant to the diagnosis of retinal venous occlusions: A review]]></article-title>
<source><![CDATA[Cien Tecnol Salud Vis Ocul]]></source>
<year>2016</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>91-111</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[MacDonald]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ABC of OVR: a review of retinal venous occlusion]]></article-title>
<source><![CDATA[Clin Exp Optom]]></source>
<year>2014</year>
<volume>97</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>311-23</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rehak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rehak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occlusion of retinal branch vein: pathogenesis, visual prognosis and treatment modalities]]></article-title>
<source><![CDATA[Curr Eye Res]]></source>
<year>2008</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-31</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guirado]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Trombosis Venosa retiniana y Trombosis venosa profunda; hablamos de dos manifestaciones de una misma enfernedad? Estudio comparwativo de 2 cohortes]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Murcia ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Católica de Murcia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jarro]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Patologías retinianas con tomografía por adherencia óptica, en Hospital Abel Gilbert entre 2014 y 2015]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Guayaquil ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Guayaquil]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shiono]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kogo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yomoda Jujo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tokuda]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kitaoka]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2018</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Eficacia y Seguridad del tratamiento con ranibizumab intravítreo en pacientes con ranibizumab intravítreo en pacientes con DMAE húmeda y edema macular secundario]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Valladolid ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Valladolid]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to the treatment and extension protocol of LUCAS]]></article-title>
<source><![CDATA[Oftalmología]]></source>
<year>2015</year>
<volume>122</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>146-52</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
